Endocyte, Inc. (NASDAQ:ECYT) presented the final overall survival (OS) analysis from the Phase 2b TARGET trial evaluating its small molecule drug conjugate (SMDC) vintafolide in combination with docetaxel in patients with FR positive recurrent NSCLC at the World Conference on Lung Cancerin Denver, Colorado.

Vintafolide plus docetaxel improved overall survival by 2.7 months in NSCLC regardless of histology (Median OS 11.5 vs. 8.8 months, OS HR=0.86, 95% CI [0.58, 1.26]). In the predefined subset analysis of patients with adenocarcinoma, which expresses higher levels of folate receptor, vintafolide plus docetaxel improved OS by 5.9 months (12.5 vs. 6.6 months, HR=0.72, 95% CI [0.44, 1.16]). OS for vintafolide as single agent was similar to docetaxel (OS 8.4 vs. 8.8 months, HR=1.02, 95% CI [0.70, 1.50]).

The study previously reported that the PFS primary endpoint was met, (HR=0.75, 95% CI [0.52, 1.09]) regardless of histology and in the adenocarcinoma subgroup (HR=0.73, 95% CI [0.46, 1.16]). The safety profile of the combination arm was consistent with those observed with docetaxel alone and vintafolide alone, though a higher rate of hematologic and peripheral neuropathy adverse events were observed in the combination arm.

“The final OS results are consistent with the biology of the folate receptor target, with higher expression levels in the adenocarcinoma subgroup. These data are important in guiding our future studies in NSCLC,” said Ron Ellis, president and CEO at Endocyte.

“Based on the results to date from the ongoing Phase 1 dose escalation trial of EC1456, we are optimistic that this agent will represent an important improvement in the treatment landscape for NSCLC,” said Alison Armour, chief medical officer.

EC1456 is a second generation folate-targeted SMDC, which delivers a more potent drug payload at higher doses than vintafolide. (Original Source)

Shares of Endocyte closed last Friday at $5.03. ECYT has a 1-year high of $9.35 and a 1-year low of $4.61. The stock’s 50-day moving average is $5.22 and its 200-day moving average is $5.78.

On the ratings front, Cantor Fitzgerald analyst Daniel Brims maintained a Buy rating on ECYT, with a price target of $21, in a report issued on August 5. The current price target represents a potential upside of 317.5% from where the stock is currently trading. According to TipRanks.com, Brims has a total average return of -0.2%, a 37.5% success rate, and is ranked #2563 out of 3747 analysts.

Endocyte Inc is a biopharmaceutical company. The Company is engaged in developing targeted therapies for the treatment of cancer and inflammatory diseases.